What is the average price target for IMMUNOME INC (IMNM) stock?
20 analysts have analysed IMNM and the average price target is 35.96 USD. This implies a price increase of 58.18% is expected in the next year compared to the current price of 22.73.
IMMUNOME INC (IMNM) Forecast, Price Target & Analyst Ratings
NASDAQ:IMNM • US45257U1088
Current stock price
22.73 USD
-0.21 (-0.92%)
At close:
22.72 USD
-0.01 (-0.04%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for IMMUNOME INC (IMNM).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 7, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.57
- Revenue Estimate
- 226.664K
Price Target Details & History
Consensus Price Target and Range
Mean target
$35.96
Upside
+ 58.18%
From current price of $22.73 to mean target of $35.96, Based on 20 analyst forecasts
Low
$30.30
Median
$36.21
High
$42.00
Price Target Revisions
1 Month
0.00%
3 Months
2.31%
Price Target Summary
20 Wall Street analysts provided a forecast for the next 12 months for IMNM. The average price target is 35.96 USD. This implies a price increase of 58.18% is expected in the next year compared to the current price of 22.73.
The average price target has been revised upward by 2.31% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.00%
IMNM was analyzed by 20 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about IMNM.
In the previous month the buy percentage consensus was at a similar level.
IMNM was analyzed by 20 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-04 | Stephens & Co. | Maintains | Overweight -> Overweight |
| 2026-03-04 | Craig-Hallum | Maintains | Buy -> Buy |
| 2026-02-12 | HC Wainwright & Co. | Initiate | Buy |
| 2026-01-15 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-12-16 | Lake Street | Maintains | Buy -> Buy |
| 2025-12-16 | Guggenheim | Maintains | Buy -> Buy |
| 2025-12-16 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-12-01 | Truist Securities | Initiate | Buy |
| 2025-11-17 | Stephens & Co. | Maintains | Overweight -> Overweight |
| 2025-09-22 | Goldman Sachs | Initiate | Buy |
| 2025-09-05 | Craig-Hallum | Initiate | Buy |
| 2025-08-25 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-08-22 | Evercore ISI Group | Initiate | Outperform |
| 2025-08-07 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-04-02 | Lake Street | Initiate | Buy |
| 2025-03-20 | Guggenheim | Maintains | Buy -> Buy |
| 2025-03-20 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-03-20 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-03-11 | LifeSci Capital | Initiate | Outperform |
| 2024-11-14 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-11-08 | Stephens & Co. | Initiate | Overweight |
| 2024-10-25 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-08-13 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-08-13 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-05-31 | Piper Sandler | Initiate | Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 7, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.57
- Revenue Estimate
- 226.664K
- Revenue Q2Q
- -92.25%
- EPS Q2Q
- -10.30%
- Number of Analysts
- 15
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
6.11%
Next Earnings Summary
IMNM is expected to report earnings on 5/7/2026. The consensus EPS estimate for the next earnings is -0.57 USD and the consensus revenue estimate is 226.66K USD.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 14.018M | 9.041M -35.50% | 6.941M -23.23% | 6.539M -5.79% | 80.256M 1,127.34% | 232.73M 189.98% | 412.21M 77.12% | 636.45M 54.40% | 872.53M 37.09% | 1.132B 29.74% | 1.433B 26.59% | |
| EBITDA YoY % growth | -28.271M 22.50% | -151.889M -437.26% | -211.647M -39.34% | -284.765M -34.55% | -275.757M 3.16% | -109.059M 60.45% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -28.728M 22.15% | -153.456M -434.17% | -214.113M -39.53% | -283.247M -32.29% | -270.248M 4.59% | -148.833M 44.93% | -12.236M 91.78% | 165.03M 1,448.71% | 364.73M 121.01% | 563.03M 54.37% | 795.92M 41.36% | |
| Operating Margin | -204.94% | -1,697.33% | -3,084.76% | -4,331.65% | -336.73% | -63.95% | -2.97% | 25.93% | 41.80% | 49.74% | 55.54% | |
| EPS YoY % growth | N/A 67.94% | -5.17 -421.82% | -2.43 53.00% | -2.51 -3.29% | -2.32 7.38% | -1.23 47.19% | 0.30 124.09% | 1.72 481.28% | 2.96 71.89% | 3.59 21.57% | 4.44 23.56% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.57 -10.30% | -0.62 -23.19% | -0.65 0.17% | -0.64 15.34% | -0.59 -2.26% | -0.60 1.80% | -0.54 16.84% | -0.48 24.70% |
| Revenue Q2Q % growth | 226.664K -92.25% | 226.664K -94.35% | 226.664K | 5.859M | 11.571M 5,004.90% | 4.126M 1,720.31% | 9.552M 4,114.16% | 17.043M 190.89% |
| EBITDA Q2Q % growth | -64.788M -47.16% | -68.148M -50.67% | -73.454M -25.99% | -78.375M -29.77% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -66.333M -48.61% | -70.156M -50.94% | -74.24M -23.45% | -74.766M -18.94% | -70.788M -6.72% | -78.132M -11.37% | -72.93M 1.77% | -70.584M 5.59% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
14.34%
EPS Next 5 Year
22.04%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
216.45%
Revenue Next 5 Year
144.10%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
14.24%
EBIT Next 5 Year
N/A
IMMUNOME INC / IMNM Forecast FAQ
What is the next earnings date for IMNM stock?
IMMUNOME INC (IMNM) will report earnings on 2026-05-07.
What are the consensus estimates for IMMUNOME INC (IMNM) next earnings?
The consensus EPS estimate for the next earnings of IMMUNOME INC (IMNM) is -0.57 USD and the consensus revenue estimate is 226.66K USD.
How many analysts have analysed IMMUNOME INC (IMNM)?
The number of analysts covering IMMUNOME INC (IMNM) is 20.